Search results
Results From The WOW.Com Content Network
The lower legs and feet of a 23-year-old woman with Waldmann’s since infancy. Waldmann disease, also known as Primary Intestinal Lymphangiectasia (PIL), is a rare disease [1] characterized by enlargement of the lymph vessels supplying the lamina propria of the small intestine. [2]
When it occurs in the intestines it is known as intestinal lymphangiectasia, colloquially recognized as Waldmann's disease in cases where there is no secondary cause. [3] The primary defect lies in the inability of the lymphatic system to adequately drain lymph, resulting in its subsequent accumulation and leakage into the intestinal lumen. [ 3 ]
Cancer survival rates vary by the type of cancer, stage at diagnosis, treatment given and many other factors, including country. In general survival rates are improving, although more so for some cancers than others. Survival rate can be measured in several ways, median life expectancy having advantages over others in terms of meaning for ...
Survival rate is a part of survival analysis.It is the proportion of people in a study or treatment group still alive at a given period of time after diagnosis. It is a method of describing prognosis in certain disease conditions, and can be used for the assessment of standards of therapy.
Five-year survival rates can be used to compare the effectiveness of treatments. Use of five-year survival statistics is more useful in aggressive diseases that have a shorter life expectancy following diagnosis, such as lung cancer, and less useful in cases with a long life expectancy, such as prostate cancer.
median overall survival time of approximately 12–16 months, with five-year survival rate of approximately 26% and the long-term survival rate of approximately 4 - 5%. Limited-stage small cell lung carcinoma (LS-SCLC) is a type of small cell lung cancer (SCLC) that is confined to an area which is small enough to be encompassed within a ...
Thomas A. Waldmann was born in New York City as the only child of Elisabeth Sipos and Charles Waldmann. He received his M.D. from Harvard Medical School in 1955. He joined the National Cancer Institute in 1956 and became chief of the Lymphoid Malignancies Branch (formerly Metabolism Branch) in 1973.
The authors concluded that trials using a patient mix weighted toward good prognosis will not find such a difference. In 1993, a retrospective analysis was performed on 2031 patients with aggressive non-Hodgkin's lymphoma, of all ages, treated with a doxorubicin -based chemotherapy regimen such as CHOP between 1982 and 1987. [ 2 ]